| References: |
Description of everolimus: Everolimus is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of Everolimus in water, the solubility of Everolimus in DMSO, the solubility of Everolimus in PBS buffer, the animal experiment（test） of Everolimus,the in vivo,in vitro and clinical trial test of Everolimus,the cell experiment（test） of Everolimus,the IC50, EC50 and Affinity of Everolimus, please contact DC Chemicals. |
